Gastric Cancer

P=N/A, N=36, Recruiting, Dartmouth-Hitchcock Medical Center | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Sep 2026 --> Sep 2027

P2, N=54, Recruiting, Yale University | Initiation date: Mar 2026 --> Jun 2026

P1, N=27, Active, not recruiting, Institut Paoli-Calmettes | Recruiting --> Active, not recruiting

This case highlights the integration of pathological features, c-kit exon 11 mutation status, and imaging findings in the diagnosis and management of high-risk GSTs. The 4-year recurrence-free survival confirms the effectiveness of risk-stratified adjuvant therapy with imatinib.

Our study reveals a previously unrecognized CaMK2A-ZDHHC3-GPX4 signaling axis that couples ferroptosis resistance to immunosuppressive TAM polarization. Targeting GPX4 or disrupting exosomal CaMK2A signaling may reprogram the TME and potentiate immune checkpoint therapy in GC.

P2, N=120, Not yet recruiting, Sichuan University

P=N/A, N=34, Recruiting, Masaryk Memorial Cancer Institute

HER2 overexpression appears to be associated with poorer outcomes in advanced and resectable gastric cancer. Standardizing diagnostic criteria and integrating HER2 assessment into multimarker panels could enhance prognostic accuracy and guide personalized therapeutic decisions.

This effect was more prominent in the neck compared to the base, which has greater abundance of CD44v after injury in Lgals8 -/- mice. Derepression of STAT3 signaling may explain why low galectin-8 levels is associated with a worse prognosis in gastric cancer.

Claudin-18 isoform 2 (CLDN18.2) has rapidly moved from a gastric-lineage surface antigen to an actionable therapeutic target in advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinoma, following the SPOTLIGHT and GLOW Phase 3 trials, which established zolbetuximab plus fluoropyrimidine-platinum chemotherapy as a first-line option for patients with CLDN18.2-positive, HER2-negative disease...Collectively, current evidence supports a reassessment-based rather than assumption-based approach to CLDN18.2 sequencing. However, key gaps remain, including the optimal interface with PD-1-based first-line therapy, the geographic generalizability of several next-generation datasets, standardized retesting strategies at progression, and prospective validation of modality-specific sequencing after target modulation.

Mechanistically, cscR-819 was predominantly localized in the cytoplasm and functioned as a translational regulator, selectively enhancing the translation efficiency of genes involved in cell cycle progression, DNA replication, and antiapoptotic pathways, as demonstrated by polyribosome profiling. In conclusion, our study establishes cscRNAs as functionally relevant contributors to gastric cancer pathogenesis and identifies exploratory associations with tumor immune microenvironment features, positioning cscRNA-based signatures as promising candidate biomarkers for risk stratification and motivating further investigation of cscRNA-immune interactions.

Moreover, this platform was successfully applied to the quantitative analysis of miRNA-21 in the serum of lung cancer and gastric cancer patients, and can in situ track the secretion behavior of tumor cell derived miRNA-21. This strategy provides new insights into the multi-scale design of temperature-biomolecular double-responsive smart nanomaterials and offers a promising strategy for advanced biosensing and bioanalytical applications.